Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or...
Patent
1995-03-06
1999-02-16
Adams, Donald E.
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
435238, 435239, 435325, C12N 700, C12N 706, C12N 702, C12N 500
Patent
active
058719970
ABSTRACT:
Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The reduction of levels of galactose alpha (1,3) galactosyl epitopes on the retroviral vector particles and/or the blockade of antibody binding to such epitopes have been found to render the particles less sensitive to inactivation by complement mediated mechanisms, and to thus allow transduction in the presence of complement containing body fluids. Means are provided for obtaining such reductions.
REFERENCES:
Leiden, 1995 New Engl. J. Med. 333:871-873.
Mulligan, 1993 Science 260:926-932.
Brenner, 1994 Immunomethods 5:204-210.
Banapour et al., "The AIDS-Associated Retrovirus is Not Sensitive to Lysis or Inactivation by Human Serum" Virology, 152:268-271, 1986.
Barbacid et al., "Humans Have Antibodies Capable of Recognizing Oncoviral Glycoproteins: Demonstration that these Antibodies are Formed in Response to Cellular Modification of Glycoproteins Rather than as Consequence of Exposure to Virus" Proc. Natl. Acad. Sci. USA, 77(3):1617-21, 1980.
Bartholomew et al., "Lysis of oncornaviruses by human serum" J Exp Med, 147:844-853, 1978.
Bartholomew and Esser, "Mechanism of antibody-independent activation of the first component of complement (C1) on retrovirus membranes" Biochem, 19:2847-2853, 1980.
Cooper et al., "Lysis of RNA tumor viruses by human serum: Direct antibody-independent triggering of the classical complement pathway" J Exp Med, 144:970-984, 1976.
Cooper et al., "Genetically Engineered Pigs" Lancet, 342:682-683, 1993.
Cornetta et al., "Amphotropic Murine Leukemia Retrovirus is not an Acute Pathogen for Primates" Human Gene Therapy, 1:15-30, 1990.
Culver et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors" Science, 256:1550-1552, 1992.
Donahue et al., "Helper Virus Induced T Cell Lymphoma in Nonhuman Primates after Retroviral Mediated Gene Transfer" J Exp Med, 176:1125-1135, 1992.
Galili et al., "Evolutionary relationship between the natural anti-Gal antibody and the Gal.alpha.1.fwdarw.3Gal epitope in primates" Proc Natl Acad Sci, USA, 84:1369-1373, 1987.
Galili et al., "Man, Apes, and Old World Monkeys Differ from Other Mammals in the Expression of .alpha.-Galactosyl Epitopes on Nucleated Cells" J Biol Chem, 263:17755-17762, 1988.
Galili et al., "Gene Sequences Suggest Inactivation of .alpha.-1,3-Galactosyltransferase in Catarrhines after the Divergence of Apes from Monkeys" Proc Natl Acad Sci, USA, 88:7401-7404, 1991, Apr. 30, 1998.
Galili et al., "Evolution and Pathophysiology of the Human Natural Anti-.alpha.-galactosyl IgG (Anti-Gal) Antibody" Springer Semin Immunopathol, 15:155-171, 1993.
Geyer et al., "Major Oligosaccharides in the Glycoprotein of Friend Murine Leukemia Virus: Structure Elucidation by One- and Two-Dimensional Proton Nuclear Magnetic Resonance and Methylation Analysis" Biochemistry, 23:5628-5637, 1984, Apr. 30, 1998.
Hamadeh et al., "Human Natural Anti-Gal IgG Regulates Alternative Complement Pathway Activation on Bacterial Surfaces" J Clin Invest, 89:1223-1235, 1992.
Hoshino et al., "Human T-Cell Leukaemia Virus is not Lysed by Human Serum" Nature, 310:324-325, 1984.
Isaacs et al., "Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence" Proc Natl Acad Sci, USA, 89:628-632, (1992).
Joziasse et al., "Bovine .alpha.1.fwdarw.3-Galactosyltransferase: Isolation and Characterization of a cDNA Clone" J Biol Chem, 264:14290-14297, 1989.
Kohn et al., "Retroviral-Mediated Gene Transfer into Mammalian Cells" Blood Cells, 13:285-298, 1987.
Larsen et al., "Molecular Cloning, Sequence, and Expression of a Human GDP-L-fucose:.beta.-D-galactoside 2-.alpha.-L-fucosyltransferase cDNA that Can Form the H Blood Group Antigen" Proc Natl Acad Sci, USA, 87:6674-6678, 1990.
Lowe, "Molecular Cloning, Expression, and Uses of Mammalian Glycosyltransferases" Semin Cell Biol, 2:289-307, 1991.
Lower et al., "Heterophil Human Antibodies Recognize Oncovirus Envelope Antigens: Epidemiological Parameters and Immunological Specificity of the Reaction" Virology, 109:409-417, 1981.
McNearney et al., "Herpes simplex virus glycoproteins gC-1 and gC-2 bind to the third component of complement and provide protection against complement-mediated neutralization of viral infectivity" J Exp Med, 166:1525-1535, 1987.
Martinez et al., "Partial Reconstitution of Replication-Competent Retrovirus in Helper Cells with Partial Overlaps Between Vector and Helper Cell Genomes" Human Gene Therapy, 7:705-712, 1996.
Neethling et al., "Protection of pig kidney (PK15) cells from the cytotoxin effect of anti-pig antibodies by .alpha.-galactosyl oligosaccharides" Transplantation, 57:959-963, 1994.
Ram et al., "Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors " J Neurosurg, 79:400-407, 1993.
Repik et al., "Differential host-dependent expression of .alpha.-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model" J Gen Virol, 75:1177-1181, 1994.
Rother et al., "Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri" J Virol, 68:730-737, 1994.
Rother et al., "Protection of Retroviral Vector Particles in Human Blood through Complement Inhibition" Human Gene Therapy, 6:429-435, 1995.
Rother et al., "A Novel Mechanism of Retrovirus Inactivation in Human Serum Mediated by Anti-.alpha.-Galactosyl Natural Antibody" J Exp Med, 182:1345-1355, 1995.
Sandrin et al., "Biochemical Features of Pig to Human Xenografts" J Leukocyte Biol, O (Suppl.) :66, 1993.
Sandrin et al., "Anti-Pig IgM Antibodies in Human Serum React Predominantly with Gal (.alpha.1-3)Gal Epitopes" Proc Natl Acad Sci, USA, 90:11391-11395, 1993.
Sandrin et al., "Gal .alpha.(1-3) Gal, the Major Xenoantigen(s) Recognized in Pigs by Human Natural Antibodies" Immunol Reviews, 141:160-190, 1994.
Sherwin et al., "Complement-Mediated Lysis of Type-C Virus: Effect of Primate and Human Sera on Various Retroviruses" Int J Cancer, 21:6-11, 1978.
Snyder et al., "Specificity of Human Antibodies to Oncovirus Glycoprotiens: Recognition of Antigen by Natural Antibodies against Carbohydrate Structures" Proc Natl Acad Sci, USA, 77:1622-1626, 1980.
Spear et al., "Direct Binding of Complement Component C1q to Human Immunodeficiency Virus (HIV) and Human T Lymphotrophic Virus-I (HTLV-|) Coinfected Cells" AIDS Research Human Retroviruses, 7:579-585. 1991.
Takeuchi et al., "Type C Retrovirus Inactivation by Human Complement Is Determined by both the Viral Genome and the Producer Cell" J Virol, 68:8001-8007, 1994.
Thall et al., "Distribution of Gal.alpha.1.fwdarw.3Gal.beta.1.fwdarw.4GlcNAc Residues on Secreted Mammalian Glycoproteins (Thyroglobulin, Fibrinogen, and Immunoglobulin G) as Measured by a Sensitive Solid-Phase Radioimmunoassay" Biochemistry, 29:3959-3965, 1990.
Thiry et al., "Factors which Influence Inactivation of Vesicular Stomatitis Virus by Fresh Human Serum" Virology, 87:384-393, 1978.
Vaughn et al., "Biochemical Analysis of Pig Xenoantigens Detected by Human Antibodies" Transplantation Proc, 25:2919-2920, 1993.
Welsh et al., "Human serum lyses RNA tumour viruses" Nature, 257:612-614, 1975.
Welsh et al., "Inactivation and lysis of oncornaviruses by human serum" Virology, 74:432-440, 1976.
Widner and Brundin, "Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis" Brain Res Rev, 13:287-324, 1988.
Fodor William L.
Rollins Scott A.
Rother Russell P.
Springhorn Jeremy P.
Squinto Stephen P.
Adams Donald E.
Alexion Pharmaceuticals, Inc.
Fidel Seth A.
Parkin Jeffrey S.
LandOfFree
Methods and compositions for protecting retroviral vector partic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for protecting retroviral vector partic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for protecting retroviral vector partic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2061582